Most studies on TP53 mutations were focused on patients with CK, 17p abnormalities or older population.9, 32, 33 In this study, we analyzed 500 consecutive patients, both cytogenetically normal and abnormal, so the frequency and clinical characteristics of TP53 mutations in unselected de novo AML patients could be known. Here, TP53 is linked to acute myeloid leukemia.